DRTS Stock Rises Overnight: Early US Brain Cancer Trial Results Expected Today

• Alpha Tau said it will discuss interim data on Monday from the first three patients treated in its U.S. Regain study evaluating Alpha DaRT in patients with recurrent Glioblastoma.
• Alpha DaRT uses implanted radium-224 sources to deliver targeted radiation directly inside tumors.
• The company has already received Breakthrough Device Designation from the FDA and submitted the first section of its pre-market approval application in January.

Shares of Alpha Tau Medical (DRTS) rose over 1% in overnight trading on Monday as investors focused on the company’s early U.S. clinical results from its brain cancer radiation therapy.

DRTS stock snapped five straight weeks of gains, ending last week marginally lower at $8.51.

Early Brain Cancer Data In Focus

The company is set to host a conference call on Monday to discuss interim data from the first three patients treated in its U.S. Regain study, which is evaluating Alpha DaRT in recurrent Glioblastoma. The Regain study is targeting patients with recurrent glioblastoma who are no longer candidates for surgery and have already undergone prior radiation treatment.

The Israel-based biotech firm expects the study to enroll up to 10 patients in the U.S. to determine whether the treatment can be delivered safely and feasibly in the patient population. Glioblastoma is considered one of the deadliest forms of brain cancer, and recurrence rates remain high even after aggressive treatment involving surgery, radiation and chemotherapy.

Alpha DaRT, short for Diffusing Alpha-emitters Radiation Therapy, can deliver radiation directly into the tumor rather than targeting it externally. The treatment uses radium-224 sources implanted in the tumor, which release short-range alpha particles intended to destroy cancer cells while minimizing exposure to healthy tissue. 

Alpha DaRT Moves Closer To FDA Path

Last week, Alpha Tau Medical said it completed enrollment in its ReStart study testing Alpha DaRT in patients with recurring skin cancer. The trial enrolled 88 patients whose cancer had returned after standard treatments and who were no longer eligible for surgery or other conventional treatment options. The study also marks Alpha Tau’s first major U.S. trial to fully enroll patients. 

Alpha Tau Medical has already received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for Alpha DaRT in recurrent skin cancer, a status that helps expedite the review process for potentially important new treatments. The company also submitted the first section of its pre-market approval application to the FDA in January. CEO Uzi Sofer called the enrollment milestone a “watershed moment” for the company.

Pancreatic Cancer Data Draws Attention

Investor interest also picked up after Alpha Tau presented updated pancreatic cancer data at Digestive Disease Week 2026 earlier this month. The company reported pooled data from two first-in-human studies involving patients with pancreatic cancer in Israel. According to Alpha Tau, all 19 evaluable patients achieved local disease control, with stable disease in 79% and partial responses in 21%.

Alpha Tau also highlighted a favorable safety profile, with most device-related side effects resolving within two weeks.

How Do Retail Traders Feel About DRTS?

On Stocktwits, retail sentiment for DRTS slipped to ‘neutral’ from ‘bullish’ levels a day ago amid over a 1,200% surge in 24-hour message volumes.

One user said, “If Alpha DaRT shows safety in the brain, this is a total game changer for the oncology space. 100% control in pancreatic and skin already proven—now we see if it can tackle the toughest one.”

Another user said, “The company you thought had a great solution for skin cancer has, in the past week, redefined itself as Pancreatic and GBM destroyers.”  

DRTS stock has jumped 191% over the past year. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: IBRX Stock Can't Shake FDA Delay Overhang: Founder Touts Saudi And Greece Progress With Anktiva As Bright Spots